News

2019-Gene-Therapy-Muscular-Dystrophy_ProgFeature_IMG

Market Access/ News/ News/ Press Releases

Solid Biosciences acquires AavantiBio, conducts $75 million private placement

Nicole Raleigh AAV, aavantbio, acquisition, BAG3, DMD, Duchenne muscular dystrophy, Friedrich's ataxia, gene therapy, M&A, merger, Solid Biosciences 0 Comment

The life sciences company Solid Biosciences is merging with the privately-held gene therapy company AavantiBio in a deal

Solid Biosciences acquires AavantiBio, conducts $75 million private placement

https://pharmaphorum.com/news/solid-biosciences-acquires-aavantibio-conducts-75-million-private-placement/

Market Access/ News/ News/ Press Releases

Translarna not approved by NICE for DMD on NHS

Nicole Raleigh ataluren, DMD, Duchenne muscular dystrophy, NICE, Translarna 0 Comment

In draft guidance published on Friday, it emerged NICE does not recommend PTC Therapeutics’ Translarna (ataluren) for the

Translarna not approved by NICE for DMD on NHS

https://pharmaphorum.com/news/translarna-not-approved-by-nice-for-dmd-on-nhs/

News/ News/ R&D/ Views & Analysis

Amylyx ALS drug draws criticism over $158,000 price tag

Nicole Raleigh ALS, Amylyx, Drug pricing, ICER, pharma, Radicava, Relyvrio 0 Comment

Amylyx Pharmaceuticals’ Relyvrio – a new treatment for amyotrophic lateral sclerosis (ALS) approved by the FDA on Thursday,

Amylyx ALS drug draws criticism over $158,000 price tag

https://pharmaphorum.com/news/amylyx-als-drug-draws-criticism-over-158000-price-tag/

News/ News/ R&D

Positive phase 3 results for Zealand Pharma’s glepaglutide

Nicole Raleigh gastrointestinal disorders, glepaglutide, SBS, short bowel syndrome, Zealand Pharma 0 Comment

Biotech company Zealand Pharma A/S, an innovator in peptide-based medicines, announced the positive topline results from its phase

Positive phase 3 results for Zealand Pharma’s glepaglutide

https://pharmaphorum.com/news/positive-phase-3-results-for-zealand-pharmas-glepaglutide/

News/ News/ R&D

Intercept hit hard as NASH trial misses the mark

Phil Taylor hepatology, Intercept Pharmaceuticals, NASH, obeticholic acid 0 Comment

Intercept Pharma’s hopes of getting its non-alcoholic steatohepatitis (NASH) therapy obeticholic acid (OCA) in the US may have

Intercept hit hard as NASH trial misses the mark

https://pharmaphorum.com/news/intercept-hit-hard-as-nash-trial-misses-the-mark/

News/ News/ Sales and Marketing

Supreme court throws Novartis a lifeline for Gilenya defense

Phil Taylor generic, Gilenya, HEC Pharma, litigation, multiple sclerosis, Novartis, patent, patent litigation 0 Comment

In a dramatic change in fortunes, Novartis has won a major victory in its bid to defend oral

Supreme court throws Novartis a lifeline for Gilenya defense

https://pharmaphorum.com/news/supreme-court-throws-novartis-a-lifeline-for-gilenya-defense/

Digital/ News/ News/ News/ Sales and Marketing

Babylon hires Andrew Hine to spearhead overseas expansion

Phil Taylor Babylon Health, digital, digital health, online consultation, senior management 0 Comment

UK digital health company Babylon has hired Andrew Hine to take charge of its international expansion efforts, as

Babylon hires Andrew Hine to spearhead overseas expansion

https://pharmaphorum.com/news/babylon-hires-andrew-hine-to-spearhead-overseas-expansion/

News/ News/ Sales and Marketing

Merck defends blockbuster Januvia franchise from patent challenge

Phil Taylor Diabetes, generic, Januvia, Merck & Co, Sales and Marketing, Viatris 0 Comment

Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition

Merck defends blockbuster Januvia franchise from patent challenge

https://pharmaphorum.com/news/merck-defends-blockbuster-januvia-franchise-from-patent-challenge/

Market Access/ News/ News

Relief for Amylyx as FDA clears controversial ALS drug Relyvrio

Phil Taylor Amylyx, amyotrophic lateral sclerosis, fda, motor neuron disease, neurology, regulatory approval, Relyvrio 0 Comment

Patient organisations have been celebrating the FDA approval yesterday of Amylyx’ amyotrophic lateral sclerosis (ALS) therapy Relyvrio, after

Relief for Amylyx as FDA clears controversial ALS drug Relyvrio

https://pharmaphorum.com/news/relief-for-amylyx-as-fda-clears-controversial-als-drug-relyvrio/

‹ 1 2 3 4 ›»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

News

Login